Patents Examined by Noble E Jarrell
  • Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents
    Patent number: 10947198
    Abstract: Chemical compounds that inhibit cancer cell growth are provided. The compounds are heteroarotinoids and derivatives thereof with oxygen, nitrogen or sulfur in chroman systems, tetrahydroquinoline systems, and tetrahydrothiochroman systems.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: March 16, 2021
    Assignee: THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY
    Inventors: Kenneth Darrell Berlin, Richard A. Bunce, Krishna Kumar Gnanasekaran, Field M. Watts, Jr., Donghua Howard Zhou
  • Spiro and cyclic bis-benzylidene proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders
    Patent number: 10947199
    Abstract: Described herein are spiro and cyclic bis-benzylidine proteasome inhibitors, which inhibit the proteasome function through either ubiquitin receptor ADRM1/RPN13 or proteasome DUB enzymes (USP14, UCH37 and RPN11), and which can be used for the treatment of cancers/diabetes/neurological disorders.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: March 16, 2021
    Assignee: UP THERAPEUTICS, INC.
    Inventor: Yung-Nien Chang
  • Therapeutic compounds and methods of use thereof
    Patent number: 10947251
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein, A, B, ring C, R3, R4, R5, R6, and R7 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: March 16, 2021
    Assignee: GENENTECH, INC.
    Inventors: Steven McKerrall, Brian Salvatore Safina, Aleksandr Kolesnikov, Birong Zhang, Wenfeng Liu, Kwong Wah Lai
  • Methods and reagents for analyzing protein-protein interfaces
    Patent number: 10948495
    Abstract: The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: March 16, 2021
    Assignee: Revolution Medicines, Inc.
    Inventors: Gregory L. Verdine, M. James Nichols, Sharon A. Townson, Uddhav Kumar Shigdel, Seung-Joo Lee, Dylan T. Stiles, Neville J. Anthony
  • Nanocomposite containing hollow silica spheres functionalized with azole silanes
    Patent number: 10947255
    Abstract: A nanocomposite containing azole modified hollow silica spheres. In particular, the nanocomposite involves a silanization reaction product of an azole-functionalized silane linker and hollow silica spheres. The azole-functionalized silane linker is produced via a ring-opening reaction a silane coupling agent having an epoxide group and an azole compound. A method of making the nanocomposite is also specified.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: March 16, 2021
    Assignee: Imam Abdulrahman Bin Faisal University
    Inventors: Sarah Mousa M. Asiri, Ayhan Bozkurt
  • Compounds for the detection, capture and/or separation of polluting gases
    Patent number: 10940425
    Abstract: A subject of the present invention is the use of a compound having the general formula (I): (I) wherein V, W, X4, X5, X6, X7, X?4, X?5, X?6, X?7, Y, Y?, R3, R?3, R4 and R?4 are as defined in any one of claims 1 to 11, for the detection, capture and/or separation of polluting gases, in particular those selected from the group comprising carbon dioxide, methane, sulfur dioxide, nitrogen oxides, carbon monoxide, linear hydrocarbons, linear mono-olefins and their mixtures, and preferably carbon dioxide. Another subject of the invention is a compound of formula (I) wherein V, W, X4, X5, X6, X7, X?4, X?5, X?6, X?7, Y, Y?, R3, R?3, R4 and R?4 are as defined in any one of claims 12 to 21.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: March 9, 2021
    Assignees: Centre National de la Recherche Scientifique, Universite d'Aix-Marseille
    Inventors: Jean-Manuel Raimundo, Vinicius Demétrio da Silva, Philip Leslie Llewellyn, Julien Rodriguez, Olivier Yves Claude Siri
  • Oxidation process to produce 5-(alkoxycarbonyl)furan-2-carboxylic acids (ACFC)
    Patent number: 10941245
    Abstract: Disclosed herein is a very efficient method to make 5-(alkoxycarbonyl)furan-2-carboxylic acids (ACFC) from feedstocks comprised of furoates. When a feedstock comprised of methyl 5-methylfuran-2-carboxylate (MMFC) is used a product comprised of (5-(methoxycarbonyl)furan-2-carboxylic acid (MCFC) is obtained in high yield.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: March 9, 2021
    Assignee: Eastman Chemical Company
    Inventor: Mesfin Ejerssa Janka
  • Conjugated lipomers and uses thereof
    Patent number: 10933139
    Abstract: The present invention provides inventive conjugated polyethyleneimine (PEI) polymers and conjugated aza-macrocycles (collectively referred to herein as “conjugated lipomers” or “lipomers”) containing one or more groups of the formula (iii): wherein R3 and R4 are as defined herein. Also provided are compositions comprising the inventive conjugated lipomers, and methods of preparation and use.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: March 2, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: James E. Dahlman, Avraham D. Schroeder, Daniel Griffith Anderson, Robert S. Langer, Christopher G. Levins
  • Donor-acceptor nanohoop compounds and methods of making and using the same
    Patent number: 10934290
    Abstract: Disclosed herein are embodiments of nanostructure compounds that exhibit unique shape configurations, such as nanohoops. The compounds disclosed herein exhibit unique chemical and electrochemical properties that can be tuned and modified to facilitate their use in a variety of different applications.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: March 2, 2021
    Assignee: University of Oregon
    Inventors: Ramesh Jasti, Evan R. Darzi
  • Heterocyclic sulfones as ROR gamma modulators
    Patent number: 10934286
    Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? Gamma activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? Gamma activity, for example, autoimmune and/or inflammatory disorders.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: March 2, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Qingjie Liu, T. G. Murali Dhar, Lan-ying Qin, Lyndon A. M. Cornelius, Hai-Yun Xiao, Jianqing Li, Robert J. Cherney
  • Material for organic electroluminescent device and organic electroluminescent device using the same
    Patent number: 10937969
    Abstract: A novel and improved material for an organic electroluminescent device includes at least one monoamine compound represented by any one of the following Formulae I to III: In Formulae I to III, Ar is a substituted or unsubstituted aryl group having 6 to 50 carbon atoms for forming a ring. The organic electroluminescent device including the material may have improved emission life.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: March 2, 2021
    Assignee: Samsung Display Co., Ltd.
    Inventors: Hideo Miyake, Ichinori Takada, Hiromi Nakano
  • Fused imidazoles as mIDH1 inhibitors
    Patent number: 10919862
    Abstract: The present invention relates to compounds of general formula (I): in which R1, R2, R3, R4, R6, R7, R8, R9, R10, R11, R12, R13 and X are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: February 16, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Olaf Panknin, Ingo Hartung, Hartmut Rehwinkel, Duy Nguyen, Ludwig Zorn, Petra Helfrich, Katja Zimmermann, Roland Neuhaus
  • Convergent and enantioselective total synthesis of Communesin analogs
    Patent number: 10918627
    Abstract: A highly convergent biomimetic synthesis of a complex polycyclic scaffold has been successfully implemented. From these efforts, compounds having a structure of Formula (I): or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1-R8 and m, n, r, s, t, and u are as defined herein, is provided. Methods of making such compounds are also disclosed as are methods for the treatment of cancer, various infectious diseases, and abnormal cardiovascular function.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: February 16, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: Mohammad Movassaghi, Stephen Paul Lathrop, Matthew W. Pompeo, Wen-Tau Timothy Chang
  • Northern-southern route to synthesis of bacteriochlorins
    Patent number: 10919904
    Abstract: Described herein are chlorins, bacteriochlorins, methods and intermediates for the synthesis of bacteriochlorins, and methods of using such bacteriochlorins for, among other things, diagnostic and therapeutic purposes such as luminescent compounds in flow cytometry, and as active agents in photodynamic therapy (PDT).
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: February 16, 2021
    Assignee: North Carolina State University
    Inventors: Yizhou Liu, Jonathan S. Lindsey, Srinivasa Rao Allu, Hikaru Fujita
  • Nitrogen-containing heterocyclic compounds as FXR modulators
    Patent number: 10919903
    Abstract: The present technology is directed to compounds, compositions, and methods related to modulation of FXR. In particular, the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, and atherosclerosis, and renal disease.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: February 16, 2021
    Assignee: Hepagene Therapeutics (HK) Limited
    Inventor: Xiaodong Xu
  • Treatment of synucleinopathies
    Patent number: 10918628
    Abstract: A modulator of PDE1A and/or PDE1C can be used as a medicament, in particular in the prevention or treatment of synucleinopathies, such as multiple system atrophy, dementia with Lewy bodies, Parkinson's disease, pure autonomic failure, rapid eye movement sleep behavior disorder, inherited synucleinopathies caused by mutations or multiplications of the SNCA gene, or synucleinopathies caused by mutations in other genes including, but not limited to, GBA, LRRK2 and PARK2.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: February 16, 2021
    Assignees: DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E. V. (DZNE), KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITÄT MÜNCHEN
    Inventors: Günter Höglinger, Matthias Höllerhage, Thomas Werner Rösler
  • Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same
    Patent number: 10912786
    Abstract: Described herein are silyl monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. Such multimer forming associations of monomers may be promoted by the proximal binding of the monomers to their target biomolecule(s). In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: February 9, 2021
    Assignees: Cornell University, Purdue Research Foundation
    Inventors: Francis Barany, Maneesh Pingle, Donald E. Bergstrom, Sarah F. Giardina, Lee Daniel Arnold
  • Heteroaryl compounds and their use as Mer inhibitors
    Patent number: 10913730
    Abstract: Compounds of formula (I) and a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, R24, X, L, n and p are as defined in the specification, are useful for treating or preventing Mer tyrosine kinase receptor modulated disease or conditions. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: February 9, 2021
    Assignee: Dong-A Socio Holdings Co., Ltd.
    Inventors: Jin Kwan Kim, Hadong Kim, Ki Moon Ryu, Seong Jin Park, Taeyoung Yoon, Mi Yeon Jang
  • Modulators of the integrated stress pathway
    Patent number: 10913727
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: February 9, 2021
    Assignee: AbbVie Inc.
    Inventors: Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
  • Benzodiazepine derivatives as CCK2/gastrin receptor antagonists
    Patent number: 10906884
    Abstract: The invention relates to benzodiazepine derivatives of formula (A) useful as CCK2/gastrin receptor antagonists, their preparation and their use in the treatment or prevention of disorders associated with CCK2/gastrin receptors, disorders caused by or associated with hypergastrinaemia, and gastric acid-related disorders.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: February 2, 2021
    Assignee: TRIO MEDICINES LTD
    Inventors: Malcolm James Boyce, Liv Thomsen, Donald Alan Gilbert, David Wood